Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Gene expression profiling wikipedia , lookup
Epigenetics in stem-cell differentiation wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Designer baby wikipedia , lookup
DNA vaccination wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
History of genetic engineering wikipedia , lookup
TRANSFER OF PLASMID DNA AND OLIGONUCLEOTIDES INTO SKELETAL MUSCLE BY MEANS OF CATIONIC LIPID-BASED VECTORS Andrea Ditadi*, Alberto Malerba*, Gianluca Occhi*, Pier Giorgio Gamba¶, Ilaria Scambi, Ian McLachlanª, David Baroni*, Libero Vitiello* * Dept. of Biology, ¶ Dept. of Pediatric Surgery, University of Padova, Italy; ª Protiva Biotherapeutics Inc., Burnaby, BC, Canada The aim of our project is to develop a lipid-based gene delivery system capable of introducing therapeutic DNA or antisense morpholino oligonucleotides into skeletal muscle after systemic delivery. We have used both DODAC-based lipopoliplexes and SPLP (stabilized plasmid-lipid particles). We had already shown that intra-arterial delivery yielded good results in skeletal muscle and we have optimized our surgical technique to inject the lipid-DNA complexes in the femoral artery. Experiments carried out on adult rats in which muscle regeneration was chemically induced in the Tibialis Anterior muscles of the lower limb showed that SPLP containing the luc reporter gene yielded expression levels higher than 1 ng luciferase per mg of muscle extract, while a GFP-coding plasmid yielded approximately 10% of transfected fibers. Importantly, we also showed that such high levels are maintained for at least three weeks after a single administration without affecting myoblasts’ viability and differentiation, both in vitro and in vivo. In our latest experiments we have transferred this protocol to a murine model, using C57BL6 animals. Somewhat surprisingly, SPLP yielded disappointing results in mice, with transfection levels 10 to 100-fold lower than in rat. Following a series of recent reports about exon-skipping therapeutic approaches, we have then applied our surgical protocol to the delivery of oligonucleotide-loaded lipoplexes to murine skeletal. Our initial results are quite encouraging, in that we have been able to restore the correct reading frame of the dystrophin mRNA in mdx mice as old as 10 months.